A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy. | MicrobiomeTrials
A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-08Est. Completion: 2027-12
Enrollment target: 28 participants
Locations
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin Municipality, China